1. Adagene's Chief Strategy Officer will engage with investors in September. 2. Two notable investor conferences are scheduled in New York City. 3. ADG126, Adagene's lead program, targets tumors with innovative technology. 4. SAFEbody is designed to minimize toxicity in healthy tissues. 5. Adagene's strategic collaborations enhance its development of antibody therapies.
The announcement of high-profile investor engagement typically boosts investor confidence. Participation in recognized conferences can lead to increased visibility and potential funding opportunities, reminiscent of similar scenarios in biotech history.
The company's participation in key conferences may lead to strategic partnerships or investor interest, significantly affecting ADAG's market perception and funding potential.
Investor interest generally surges around conferences, impacting stock price quickly. Similar conference participation by biotech firms has historically resulted in short-term gains due to increased media and investor attention.
SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at two investor conferences in September, both taking place in New York, New York.
H.C. Wainwright 27th Annual Global Investment Conference
Morgan Stanley 23rd Annual Global Healthcare Conference
A webcast of the presentations will be accessible in the Investors section of the company's website at https://www.adagene.com for at least 30 days.
About Adagene
Adagene Inc. (NASDAQ:ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene's highly differentiated pipeline features novel immunotherapy programs. The company's SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene's lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and X.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor Contacts:
Raymond Tam
raymond_tam@adagene.com
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
